Targeting STAT3 as a potential cancer therapy has been extensively investigated [159], and recently new small-molecule inhibitors have been developed which show to inhibit IL-6-induced STAT3 activation and nuclear translocation in HCC cells [160]. Here, IL6 is linked to hepatocellular carcinoma.